Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study
Phase of Trial: Phase II/III
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Dolutegravir (Primary) ; Efavirenz; Lamivudine; Tenofovir
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Acronyms DOLPHIN-1
- 24 Sep 2019 Status changed from active, no longer recruiting to completed.
- 07 Mar 2019 Results (n=28) presented at the 26th Conference on Retroviruses and Opportunistic Infections
- 09 Oct 2018 Planned End Date changed from 1 May 2018 to 1 Dec 2018.